Bristol Myers - Celgene CVRPreferred / convertible

13F holders, Q3 2024 (September 30)

Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q2 2024Q1 2024

21holders +3

2new positions

0sold out

1famous investor

$8.78avg. 13F price*

At the end of Q3 2024, 21 institutions reported holding Bristol Myers - Celgene CVR in their 13F filings, up 3 from Q2 2024. 2 opened new positions and 0 sold out. The largest holders were FourWorld Capital Management LLC ($5.2M), Transcend Capital Advisors, LLC ($6K) and Susquehanna International Group, LLP ($5K). One famous investor held it Ken Griffin ( of Citadel Advisors's portfolio).

Company: Bristol Myers - Celgene CVR
CUSIP: 110122140
Latest filing quarter: Q2 2026

History

Number of 13F holders

Total Exit/New Position Q2 2024 → Q3 2024

	Institutions	Total Value
New Positions	2	$1K
Exits	0	$0

All 13F filers, Q2 2024 → Q3 2024: 79,207 shares bought and 9,177 shares sold, net +70,030 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.

Ownership 21 holders


FourWorld Capital Management LLC	—	No change	100,000	$5.2M
Transcend Capital Advisors, LLC	—	No change	117,775	$6K
Susquehanna International Group, LLP	—	Reduce -7.2%	113,375	$5K
DAVENPORT & Co LLC	—	No change	83,970	$4K
Bank of America Corp.	—	Add +2709.5%	51,638	$2K
Citadel Advisors	—	Reduce -0.9%	37,572	$2K
Fifth Third Bancorp	—	No change	20,000	$960
Two Sigma Securities, LLC	—	New	15,771	$757
Private Advisor Group, LLC	—	No change	15,000	$720
Watts Gwilliam & Co., LLC	—	—	20,000	$700
Trivium Point Advisory, LLC	—	New	10,000	$600
UBS Group AG	—	Add +11729.0%	3,667	$176
Northwestern Mutual Wealth Management Co.	—	No change	341	$17
Rothschild Investment LLC	—	No change	166	$8
International Assets Investment Management, LLC	—	No change	175	$8
Morgan Stanley	—	Reduce -27.4%	119	$6
Oakworth Capital, Inc.	—	No change	125	$6
JPMorgan Chase & Co.	—	No change	23	$1
Wells Fargo & Company	—	No change	28	$1
Atlantic Edge Private Wealth Management, LLC	—	No change	16	$1
Royal Bank of Canada	—	No change	2,475	$0

"% of holder's portfolio" is BRISTOL MYERS - CELGENE CVR's weight in each manager's 13F, not the share of Bristol Myers - Celgene CVR the manager owns.